Dani Bach has been appointed as Non-Executive Director of the Crescendo Biologics. Dani replaces Rob Woodman as the representative for IP Group, now one of the largest shareholders of the company. Dani has extensive investment experience in areas ranging from medical devices to protein therapeutics. He is currently Partner, Life Sciences at IP Group, having joined Touchstone Innovations in January 2016. Prior to this, he was Managing Partner at Aravis, where he co-led the design of the investment strategy, fund raising and investment process. Dani also previously worked at Index Ventures, where he helped to build companies such as Levicept and Versartis.